Timber Pharmaceuticals Announces Appointment of Dr. Gianluca Pirozzi and Edward J. Sitar to Board of Directors
June 04 2020 - 8:00AM
via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the
“Company”) (NYSE American: TMBR), a biopharmaceutical company
focused on the development and commercialization of treatments for
orphan dermatologic diseases, today announced the appointment of
Gianluca Pirozzi, M.D., Ph.D. and Edward J. Sitar to its Board of
Directors.
“We are pleased to welcome Dr. Pirozzi and Mr. Sitar to the
Board as we continue to advance innovative clinical research
evaluating novel treatments for rare dermatologic diseases with
limited options,” said John Koconis, Chief Executive Officer of
Timber. “Their experience supporting the success of public and
private companies will be invaluable to us as we expand our
clinical development programs in the years ahead.”
Dr. Pirozzi is currently Senior Vice President, Head of
Development, Hematology, Nephrology and Translational Services at
Alexion Pharmaceuticals. He also serves on the Board of Directors
of Imbria Pharmaceuticals and is a scientific advisor for the Smith
Magenis Syndrome Research Foundation. Dr. Pirozzi brings nearly two
decades of experience in drug development, previously serving
various roles at Sanofi including Head of Development, Rare
Diseases. He holds an M.D. from Università Campus Bio-Medico di
Roma and a Ph.D. in immunology from Sapienza Università di Roma and
completed a post-doc in immunology at the Pasteur Institute in
Paris, France.
“I am excited to have the opportunity to help people living with
some of the most serious conditions in medical dermatology,” said
Dr. Pirozzi. “Timber is well positioned to advance innovative
clinical research in areas of high unmet need, and I look forward
to joining the Board and supporting the team.”
Mr. Sitar has more than two decades of experience managing
finances for companies in healthcare IT and services, medical
devices and pharmaceuticals. He is currently the Chief Financial
Officer of Innovate Biopharmaceuticals, Inc. and previously served
various roles at CareDox, Inc., Ammon Analytical Laboratory, Cancer
Genetics, Inc., Healthagen, ActiveHealth Management, Cadent
Holdings, Inc., MIM Corporation (now BioScrip, Inc.), Vital Signs,
Inc., Zenith, and Coopers & Lybrand. Mr. Sitar holds a B.S. in
accounting from the University of Scranton and is licensed as a
Certified Public Accountant in New Jersey.
"I am really excited to work with the team at Timber as we build
a dermatology company that assists patients whose needs are
currently unmet,” said Mr. Sitar. “The Timber team has unparalleled
experience and I look forward to guiding them as we build a
financially strong and successful company.”
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases.
The company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing, and control) and
safety profiles. Timber is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas in tuberous
sclerosis complex (TSC), and localized scleroderma. For more
information, visit www.timberpharma.com.
For more information, contact:
Timber Pharmaceuticals, Inc. John Koconis Chief
Executive Officerjkoconis@timberpharma.com
Investor Relations:Stephanie PrincePCG Advisory(646)
762-4518sprince@pcgadvisory.com
Media Relations: Adam DaleyBerry & Company Public Relations
212-253-8881adaley@berrypr.com
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Sep 2023 to Sep 2024